Phase I trial evaluating the immunogenicity of H4IC in patients with latent tuberculosis who have received the BCG vaccine

Trial Profile

Phase I trial evaluating the immunogenicity of H4IC in patients with latent tuberculosis who have received the BCG vaccine

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2012

At a glance

  • Drugs H4IC (Primary)
  • Indications Tuberculosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Jan 2012 Enrolment was completed in 2008, and analysis of the clinical samples is ongoing, according to sanofi pasteur.
    • 04 Dec 2007 Status change from planning to recruiting.
    • 26 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top